Ann: Appendix 4C - quarterly, page-21

While I don't believe a capital raise is necessary it could be a benefit to MSB. Bring on the FDA BLA , add a couple of partnership announcements. Update the market in regards to the progress of CHF and CLBP and announce the plan for the RA product , possibly across multiple decease indications with inflammation being the key endpoint. Sell the complete plan to the world. Now would a SP of several times higher be unlikely? I don't think so, this is when a capital raise should be done . We may even be able to rejoice knowing that a few pests commonly known as shorters would be funding us for a couple of years with only 30- 40 million shares added to the book.